Strategic acquisition targets Turkish pharma growth

EarlyHealth Group, a leading global pharmaceutical service provider, has announced the acquisition of Corena Ecza Deposu, Turkey’s foremost pharmaceutical distributor. This move significantly expands EarlyHealth’s presence in the Turkish life sciences market and supports its ambitious $100 million growth strategy aimed at internationalising Türkiye’s pharmaceutical sector.

The acquisition merges Corena’s deep national expertise with EarlyHealth’s global platform, accelerating government-backed export initiatives and boosting collaboration between academia and industry. It also enhances Turkey’s role in clinical research and pharmaceutical innovation.

Dr Dan A Renout, CEO of EarlyHealth Group, commented: “Combining forces with Corena positions us to advance Turkey’s pharmaceutical export capabilities and foster innovation through strengthened partnerships. This acquisition aligns with our vision to support sustainable growth in emerging life sciences markets.”

Mrs Nihal Aygün, Corena’s owner, said: “Our long-standing partnership with EarlyHealth now reaches a new milestone. Together, we’re committed to reducing Turkey’s reliance on pharmaceutical imports and elevating the country’s status in the global supply chain.”

The signing ceremony took place in Dubai, attended by prominent figures including His Excellency Onur Saylan, Consul General of Türkiye, and members of the Abu Dhabi Royal Family, highlighting the strategic importance of the partnership for cross-border healthcare innovation and investment.

More information online